Company Description
Carmot Therapeutics is a clinical-stage biotechnology company dedicated to developing life-changing therapeutics for people living with metabolic diseases including obesity and diabetes.
We are developing our broad, wholly-owned pipeline of novel incretin agonists, using our Chemotype Evolution platform, with the potential to address these shortcomings and produce significant weight loss and glycemic control.
Our patient-focused portfolio has the potential to provide differentiated solutions for every patient’s individual metabolic health journey.
We have three clinical-stage product candidates. In June 2023, we announced proof-of-concept data from our ongoing Phase 1/2 multiple ascending dose (MAD) clinical trial for CT-388 that we are developing for patients with obesity and T2D.
We are developing CT-996, an oral small molecule, in an ongoing Phase 1 first-in-human clinical trial in participants with overweight or obesity and in cohorts of participants with overweight or obesity and T2D.
We are developing CT-868 as an adjunct to insulin for the treatment of T1D participants with overweight or obesity.
| Country | United States |
| Founded | 2008 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 59 |
| CEO | Heather Turner |
Contact Details
Address: 740 Heinz Avenue Berkeley, CA 94710 United States | |
| Phone | (888) 402-4674 |
| Website | carmot.us |
Stock Details
| Ticker Symbol | CRMO |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001490109 |
| Employer ID | 26-1872684 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Heather Turner | President, Chief Executive Officer and Director |
| Manu Chakravarthy, M.D., Ph.D. | Chief Medical and Scientific Officer |
| Michael Gray | Chief Operating Officer and Chief Financial Officer |
| Tim Garnett, M.B.B.S., F.F.P.M., F.R.C.O.G. | Director |
| Stig K. Hansen, Ph.D. | Director |
| Tim Kutzkey, Ph.D. | Director |
| Charles Newton | Director |
| Anne M. Phillips, M.D. | Director |
| Peter Svennilson | Director |
| Aetna Wun Trombley, Ph.D. | Director |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Dec 11, 2023 | RW | Filing |
| Nov 20, 2023 | S-1/A | [Amend] General form for registration of securities under the Securities Act of 1933 |
| Nov 17, 2023 | S-1 | General form for registration of securities under the Securities Act of 1933 |
| Nov 1, 2023 | DRS/A | [Amend] [Cover] Draft Registration Statement |
| Sep 28, 2023 | DRS | [Cover] Draft Registration Statement |
| Jun 6, 2023 | D | Notice of Exempt Offering of Securities |
| Aug 8, 2022 | D | Notice of Exempt Offering of Securities |
| Oct 1, 2020 | D | Notice of Exempt Offering of Securities |
| Aug 25, 2017 | D | Notice of Exempt Offering of Securities |
| Jul 17, 2012 | D | Notice of Exempt Offering of Securities |